Can Flexible Treatment Administration Impact Outcomes in Inflammatory Bowel Disease? (Takeda Pharmaceuticals International AG)

Severine Vermeire     Charlie W. Lees  1     Edouard Louis  2    
1 University of Edinburgh, Western General Hospital - GI Unit - Molecular Medicine Centre, University
2 CHU Liège Dept. de Gastroenterologie

Session
Can Flexible Treatment Administration Impact Outcomes in Inflammatory Bowel Disease? (Takeda Pharmaceuticals International AG)

Conference
UEG Week Virtual 2020

Publisher

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing